CO5160321A1 - Novedosas composiciones de tipranavir y ritonavir - Google Patents

Novedosas composiciones de tipranavir y ritonavir

Info

Publication number
CO5160321A1
CO5160321A1 CO99069669A CO99069669A CO5160321A1 CO 5160321 A1 CO5160321 A1 CO 5160321A1 CO 99069669 A CO99069669 A CO 99069669A CO 99069669 A CO99069669 A CO 99069669A CO 5160321 A1 CO5160321 A1 CO 5160321A1
Authority
CO
Colombia
Prior art keywords
tipranavir
ritonavir
new compositions
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CO99069669A
Other languages
English (en)
Spanish (es)
Inventor
James J Ferry
John R Baldwin
Marie T Borin
Original Assignee
Pharmascia And Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascia And Upjohn Company filed Critical Pharmascia And Upjohn Company
Publication of CO5160321A1 publication Critical patent/CO5160321A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO99069669A 1998-11-04 1999-11-04 Novedosas composiciones de tipranavir y ritonavir CO5160321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04

Publications (1)

Publication Number Publication Date
CO5160321A1 true CO5160321A1 (es) 2002-05-30

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99069669A CO5160321A1 (es) 1998-11-04 1999-11-04 Novedosas composiciones de tipranavir y ritonavir

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ES2298286T3 (es) * 2000-10-31 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona.
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
KR20050085681A (ko) * 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 p450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(nnrti)를함유하는 배합물의 용도
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
EP1610781A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
EP1812069A2 (en) * 2004-11-08 2007-08-01 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and etravirine
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
WO2006060175A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
WO2006060177A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
JP2008521896A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びgw695634を共に投与することを含むhiv感染症の治療方法
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
MX2012011415A (es) * 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
AU2012262322B2 (en) * 2011-05-30 2016-11-03 Autotelic Llc Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
JP2002528502A (ja) 2002-09-03
EP1126847A1 (en) 2001-08-29
CN1154491C (zh) 2004-06-23
CN1324237A (zh) 2001-11-28
BR9914940A (pt) 2001-07-10
PE20001296A1 (es) 2000-11-23
CA2346131A1 (en) 2000-05-11
WO2000025784A1 (en) 2000-05-11
CA2346131C (en) 2013-01-15
AU762349B2 (en) 2003-06-26
MY118526A (en) 2004-11-30
TW580387B (en) 2004-03-21
AU1440400A (en) 2000-05-22
HK1040625B (zh) 2005-04-01
US6147095A (en) 2000-11-14
HK1040625A1 (en) 2002-06-21

Similar Documents

Publication Publication Date Title
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
SE9504661D0 (sv) New compounds
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
BR0108537A (pt) Composições adequadas para administração oral, kits e métodos das mesmas para a hidratação de pele de mamìferos
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
FI972387L (fi) Iholle levitettäviä parasitisidikoostumuksia
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
SE9802208D0 (sv) Novel compounds
TR199802769T2 (xx) Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
PA8449301A1 (es) Composiciones farmaceuticas
DE69117303D1 (de) Zusammensetzung mit psyllium
ITRM910430A1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
SE9802209D0 (sv) Novel compounds
SE9504662D0 (sv) New compounds
IT8119868A0 (it) Delle sostanze cheratiniche, composizioni per l'idratazione costituite da solfossidi di alfa-ammino-acidi.
DE69207777D1 (de) Körperpflegemittel
IT8021550A0 (it) Derivati adenosinici ad attivita'antinfiammatoria ed analgesica e composizioni terapeutiche che licontengono come principio attivo.
BR0009194A (pt) Composição do resorcinol
CO5180574A1 (es) Micofenolato mofetil en asociacion con peg-inf-a
ES2086536T3 (es) Uso de ketorolaco para el tratamiento de la enfermedad periodontal.
ES2182524T3 (es) Composiciones de hidroxiomeprazol y sus utilizaciones.
IT1142164B (it) Composizione farmaceutica per l'impiego in un aumento di pressione endocranica